sorafenib (Nexavar)
Jump to navigation
Jump to search
Introduction
Trademark: Nexavar, FDA approved 2005
Indications
- advanced kidney cancer (renal cell carcinoma)
- gastrointestinal stromal tumor
- hepatocellular carcinoma[3]
- metastatic thyroid carcinoma[2][4]
- may be of benefit for induction & maintenance of AML in patients < 60 years of age[5]
Adverse effects
- fatigue
- hypertension
- rash, hands, feet[3]
- thrombosis, thrombotic microangiopathy[6]
- cardiotoxicity
- hypothyroidism
Laboratory
Mechanism of action
Manufacturer: Bayer/Onyx
More general terms
References
- ↑ Prescriber's Letter 13(2): 2006 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220215&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 2.0 2.1 Physician's First Watch, June 3, 2013 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
Brose MS et al Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. 2013 ASCO Meeting Abstract J Clin Oncol 31, 2013 (suppl; abstr 4) http://meetinglibrary.asco.org/content/112795-132 - ↑ 3.0 3.1 3.2 Medical Knowledge Self Assessment Program (MKSAP) 16, 17 American College of Physicians, Philadelphia 2012, 2015
- ↑ 4.0 4.1 FDA News Release: Nov. 22, 2013 FDA approves Nexavar to treat type of thyroid cancer http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376443.htm
- ↑ 5.0 5.1 O'Neil A, Short NJ AML: TKI Sorafenib Added to '7+3' Equals EFS Benefit. The multiple kinase inhibitor targets several different pathways important for AML development and maintenance. MedPage Today. Jan 11, 2018 https://www.medpagetoday.com/reading-room/asco/hematologic-malignancies/70405
Rollig C, et al The addition of sorafenib to standard AML treatment results in a substantial reduction in relapse risk and improved survival. Updated results from long-term follow-up of the randomized- controlled Soraml Trial. American Society of Hematology (ASH) 2017; Abstract 721. - ↑ 6.0 6.1 NEJM Knowledge+ Nephrology/Urology